News
Kelonia Therapeutics Presents First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting
100% MRD-negative response rate in four patients; all remain in response through the longest follow up of 5 months Favorable toxicity profile with no CRS grade 3 or above and no ICANS Potent CAR-T expansion from a single, an off-the-shelf infusion without...
Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting
Early results from the Phase 1 inMMyCAR™ study demonstrate ongoing MRD-negative responses in all patients with a tolerable safety profile Robust CAR-T cell expansion occurred in the absence of preparative chemotherapy Persistent, memory CAR-T cells in all...
Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies
Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a strategic collaboration with Johnson & Johnson* to advance the discovery of novel in vivo CAR-T cell therapies. The collaboration aims to develop...
Kelonia Therapeutics Doses First Patient in Phase 1 inMMyCAR Study Evaluating in vivo CAR T-Cell Therapy for Relapsed and Refractory Multiple Myeloma
KLN-1010 is the first anti-BCMA in vivo CAR-T program studied in a multi-center clinical trial KLN-1010 is administered directly to patients without apheresis, ex vivo manufacturing or lymphodepletion BOSTON--Kelonia Therapeutics, Inc., a biotech company...
Kelonia Therapeutics to Present iGPS® Preclinical Data at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting
BOSTON, Mass., May 9, 2025 - Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced new preclinical data of its in vivo Gene Placement System (iGPS®) will be highlighted at the...
Kelonia Therapeutics to Participate in Upcoming Scientific Conferences
BOSTON, Mass., May 2, 2024 - Kelonia Therapeutics, Inc., a biotech company revolutionizing in vivo gene delivery, announced preclinical data from its lead in vivo CAR-T cell therapeutic candidate KLN-1010 in multiple myeloma that will be highlighted at two upcoming...
Kelonia Therapeutics to Present Preclinical Data Highlighting Therapeutic Potential of in vivo CAR-T Cell Therapy in Multiple Myeloma
– Preclinical data supports potential for iGPS® particles to provide off-the-shelf in vivo CAR-T Cell therapies without need for lymphodepleting chemotherapy – BOSTON, Mass., April 2, 2024 - Kelonia Therapeutics, a biotech company revolutionizing in vivo gene...
Kelonia Therapeutics Appoints Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to Board of Directors
– World-renowned leaders in cell therapy, drug discovery and development join Kelonia as it moves toward early clinical development of in vivo CAR-T cell therapies – BOSTON, Mass., March 28, 2024 - Kelonia Therapeutics, a biotech company revolutionizing in vivo gene...
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
- Innovative universal, off-the-shelf in vivo CAR-T Cell therapy - TOKYO and BOSTON, Mass., February 15, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Kelonia Therapeutics (CEO, Founder: Kevin Friedman, Ph.D., “Kelonia”)...
Kelonia Therapeutics Presents Research Highlighting Potential of iGPS® in vivo Gene Therapy to Bring Safe, Effective CAR T Therapies to Common Medical Practice for Treatment of All Multiple Myeloma Patients
Kelonia Therapeutics Presents Research Highlighting Potential of iGPS® in vivo Gene Therapy to Bring Safe, Effective CAR T Therapies to Common Medical Practice for Treatment of All Multiple Myeloma Patients Preclinical data in mice and non-human primates demonstrate...